Clinical Trials Logo

AMD clinical trials

View clinical trials related to AMD.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02625376 Terminated - Clinical trials for Age-related Macular Degeneration

Resveratrol for Exudative Age-Related Macular Degeneration

AGED
Start date: August 6, 2015
Phase: N/A
Study type: Interventional

This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.

NCT ID: NCT02348359 Terminated - Clinical trials for Macular Degeneration

X-82 to Treat Age-related Macular Degeneration

Start date: March 16, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.

NCT ID: NCT02226835 Terminated - Clinical trials for Age-Related Macular Degeneration

Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198

Start date: August 13, 2014
Phase:
Study type: Observational

Background: - Alzheimer s disease affects the brain and causes memory and thinking problems in older people. Macular degeneration (MD) is an eye condition. It is the leading reason that people over age 55 in the United States lose their central vision. Central vision is important for seeing fine details and for tasks like reading and driving. A feature of Alzheimer s disease is plaques in the brain. A feature of age-related MD is deposits in the retina in the eye. Researchers want to learn more about these diseases and find out if they are related. Objective: - To see whether there is a relationship between Alzheimer s disease and age-related macular degeneration. Eligibility: - People with or without Alzheimer s disease enrolled in another study. Participants must have someone to help them take part in this study. Design: - Participants will be screened through the other study. They will have 1 visit. The tests will take about 3 hours. - Participants will answer questions about their medical and eye history. - Participants will have an eye exam to test how well they see. Their eye pressure will be measured and their eye movements will be checked. - Participants will get eye drops to dilate their pupils. Researchers will take pictures of the retina and the inside of the eye. Researchers may measure the thickness of the retina. - Participants will continue to receive care from their regular eye doctor during and after the study.

NCT ID: NCT00333216 Terminated - AMD Clinical Trials

Anecortave Acetate Risk-Reduction Trial (AART)

Start date: May 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.

NCT ID: NCT00332657 Terminated - AMD Clinical Trials

Anecortave Acetate Risk Reduction Trial (AART)

Start date: September 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.